Taysha Gene Therapies to Participate in Upcoming William Blair Biotech Focus Conference 2022

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) announced its participation in the William Blair Biotech Focus Conference 2022 on July 13, 2022. The company's President and CEO will join a panel discussion titled “AAV Gene Therapy: Delivery and Beyond” at 10:00 am ET. This event focuses on the company's mission to develop and commercialize innovative AAV-based gene therapies for treating monogenic central nervous system diseases. A webcast of the discussion will be available on Taysha's corporate website and archived for 60 days.

President, Founder and Chief Executive Officer to participate in “AAV Gene Therapy: Delivery and Beyond” panel discussion on Wednesday, July 13, 2022 at 10:00 am ET

DALLAS, July 06, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a panel discussion on Wednesday, July 13^th at the upcoming William Blair Biotech Focus Conference 2022.

A webcast of the event will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.

Conference Details:

Event:	William Blair Biotech Focus Conference 2022
Topic:	AAV Gene Therapy: Delivery and Beyond
Date:	Wednesday, July 13, 2022
Time:	10:00 am ET
Format:	Panel Discussion
Participants:	Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, Chief Medical Officer and Head of Research and Development of Taysha

About Taysha Gene Therapies        

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

Company Contact:
Kimberly Lee, D.O.
Chief Corporate Affairs Officer
Taysha Gene Therapies
klee@tayshagtx.com

Media Contact:
Carolyn Hawley
Canale Communications
carolyn.hawley@canalecomm.com

FAQ

What is the date and time of Taysha Gene Therapies' panel discussion at the William Blair Biotech Focus Conference 2022?

The panel discussion is scheduled for July 13, 2022, at 10:00 am ET.

What is the topic of Taysha Gene Therapies' panel discussion at the conference?

The topic is 'AAV Gene Therapy: Delivery and Beyond'.

Who is representing Taysha Gene Therapies in the panel discussion?

Suyash Prasad, the Chief Medical Officer and Head of Research and Development, will represent Taysha.

Where can I watch the Taysha Gene Therapies panel discussion?

The discussion will be available via webcast on Taysha's corporate website.

How long will the webcast of Taysha Gene Therapies' panel discussion be available?

The archived version will be available for 60 days.

What does Taysha Gene Therapies focus on in their research?

Taysha focuses on developing AAV-based gene therapies for monogenic diseases of the central nervous system.